Arsenic trioxide controllable-releasing balloon and preparing method thereof

Abstract

The invention discloses an arsenic trioxide controllable-releasing drug balloon. The quick water soluble performance of arsenic trioxide is used. The arsenic trioxide and a slow-releasing layer are coated on the surface of the balloon. Even minitype concave holes which restrain releasing of the arsenic trioxide are formed on the slow-releasing layer. The size of the concave holes is adjusted, so that the concave holes are expanded to form micro holes in the process of expanding of the balloon, the facts that the arsenic trioxide is quickly released on a vascular wall and is evenly gathered on the surface of the vascular wall are achieved, quick phagocytosis of a cell is used, proliferation of the cell is avoided, and accordingly the effect that restenosis is avoided is achieved, the balloon can be used for expansion of a percutaneous transluminal coronary angioplasty (PTCA) operation and combination with the PTCA operation and bare stents, and the influence on restenosis caused by drug stent lay-coated materials is lowered.

Description

technical field [0001] The invention relates to a medicine balloon, in particular to a balloon with controllable release of arsenic trioxide and a preparation method thereof, which can be used in combination with PTCA operation and bare stent. Background technique [0002] Arsenic trioxide (As 2 o 3 ) is the main component of traditional Chinese medicine arsenic, which has been used to treat various diseases such as malignant tumors in the medical research of our country. As a kind of medicine, natural arsenic compounds have been used in my country for more than a thousand years. In the 1970s, hematologists used As 2 o 3 It has achieved remarkable curative effect in the treatment of promyelocytic leukemia. In recent years As 2 o 3 It is also used in the treatment of solid tumors. Zhang Zhuoqi et al. and Shao Jianwei et al. found that it has anti-proliferation, pro-apoptosis and cell cycle arrest effects on VSMCs, and is important for reducing the number of cells in th...

AI Technical Summary

Problems solved by technology

However, in the above patents, in the drug selection, the arsenic trioxide drug is abandoned, so its application in this field is still a blank, and the drug is located on the surface of the coating, so that there are non-operative drugs in the drug of the balloon product itself. Loss and uneven administration. At the same time, changes in the structure of the balloon also increase the risk of the product being used in clinical operations, thus affecting the therapeutic effect of the product

[0010] Therefore, the existing drug balloons cannot well meet the needs of clinical use.

Images